Dementia Associated with Alzimer’s Disease Market, Global Outlook and Forecast 2023-2029

Report ID: MMG251094 | Category: Medical Care | Pages: 60 | Format: PDF | Published Date: October 26,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3250.00 Multi User-$4225.00

Report Description
View Table of Contents

Report Summary

The global dementia associated with Alzheimer’s disease market has been segmented based on drug class and distribution channel. In terms of drug class, the global market has been classified into cholinergic/ cholinesterase (ChE) inhibitor, memantine, and combined drug (memantine & donepezil) and others. The cholinergic/ cholinesterase (ChE) inhibitor segment dominates the dementia associated with Alzheimer’s disease market,
This report aims to provide a comprehensive presentation of the global market for Dementia Associated with Alzimer’s Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dementia Associated with Alzimer’s Disease. This report contains market size and forecasts of Dementia Associated with Alzimer’s Disease in global, including the following market information:
Global Dementia Associated with Alzimer’s Disease Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Dementia Associated with Alzimer’s Disease market was valued at US$ 4334.1 million in 2022 and is projected to reach US$ 5131.4 million by 2029, at a CAGR of 2.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Cholinergic/ Cholinesterase (ChE) Inhibitors Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Dementia Associated with Alzimer’s Disease include Merz Pharma, Novartis, Allergan, Pfizer, Daiichi Sankyo Company, Ono Pharmaceutical, Johnson & Johnson, Eisai and H. Lundbeck, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Dementia Associated with Alzimer’s Disease companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Dementia Associated with Alzimer’s Disease Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Dementia Associated with Alzimer’s Disease Market Segment Percentages, by Type, 2022 (%)
    Cholinergic/ Cholinesterase (ChE) Inhibitors
    Memantine
    Combined Drug (Memantine & Donepezil)
    Others
Global Dementia Associated with Alzimer’s Disease Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Dementia Associated with Alzimer’s Disease Market Segment Percentages, by Application, 2022 (%)
    Hospital Pharmacies
    Retail
    Online Sales
Global Dementia Associated with Alzimer’s Disease Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Dementia Associated with Alzimer’s Disease Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Dementia Associated with Alzimer’s Disease revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Dementia Associated with Alzimer’s Disease revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Merz Pharma
    Novartis
    Allergan
    Pfizer
    Daiichi Sankyo Company
    Ono Pharmaceutical
    Johnson & Johnson
    Eisai
    H. Lundbeck
    F. Hoffmann-La Roche
Outline of Major Chapters:
Chapter 1: Introduces the definition of Dementia Associated with Alzimer’s Disease, market overview.
Chapter 2: Global Dementia Associated with Alzimer’s Disease market size in revenue.
Chapter 3: Detailed analysis of Dementia Associated with Alzimer’s Disease company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Dementia Associated with Alzimer’s Disease in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

1 Introduction to Research & Analysis Reports
    1.1 Dementia Associated with Alzimer’s Disease Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Dementia Associated with Alzimer’s Disease Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Dementia Associated with Alzimer’s Disease Overall Market Size
    2.1 Global Dementia Associated with Alzimer’s Disease Market Size: 2022 VS 2029
    2.2 Global Dementia Associated with Alzimer’s Disease Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Dementia Associated with Alzimer’s Disease Players in Global Market
    3.2 Top Global Dementia Associated with Alzimer’s Disease Companies Ranked by Revenue
    3.3 Global Dementia Associated with Alzimer’s Disease Revenue by Companies
    3.4 Top 3 and Top 5 Dementia Associated with Alzimer’s Disease Companies in Global Market, by Revenue in 2022
    3.5 Global Companies Dementia Associated with Alzimer’s Disease Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Dementia Associated with Alzimer’s Disease Players in Global Market
        3.6.1 List of Global Tier 1 Dementia Associated with Alzimer’s Disease Companies
        3.6.2 List of Global Tier 2 and Tier 3 Dementia Associated with Alzimer’s Disease Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Dementia Associated with Alzimer’s Disease Market Size Markets, 2022 & 2029
        4.1.2 Cholinergic/ Cholinesterase (ChE) Inhibitors
        4.1.3 Memantine
        4.1.4 Combined Drug (Memantine & Donepezil)
        4.1.5 Others
    4.2 By Type - Global Dementia Associated with Alzimer’s Disease Revenue & Forecasts
        4.2.1 By Type - Global Dementia Associated with Alzimer’s Disease Revenue, 2018-2023
        4.2.2 By Type - Global Dementia Associated with Alzimer’s Disease Revenue, 2024-2029
        4.2.3 By Type - Global Dementia Associated with Alzimer’s Disease Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Dementia Associated with Alzimer’s Disease Market Size, 2022 & 2029
        5.1.2 Hospital Pharmacies
        5.1.3 Retail
        5.1.4 Online Sales
    5.2 By Application - Global Dementia Associated with Alzimer’s Disease Revenue & Forecasts
        5.2.1 By Application - Global Dementia Associated with Alzimer’s Disease Revenue, 2018-2023
        5.2.2 By Application - Global Dementia Associated with Alzimer’s Disease Revenue, 2024-2029
        5.2.3 By Application - Global Dementia Associated with Alzimer’s Disease Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global Dementia Associated with Alzimer’s Disease Market Size, 2022 & 2029
    6.2 By Region - Global Dementia Associated with Alzimer’s Disease Revenue & Forecasts
        6.2.1 By Region - Global Dementia Associated with Alzimer’s Disease Revenue, 2018-2023
        6.2.2 By Region - Global Dementia Associated with Alzimer’s Disease Revenue, 2024-2029
        6.2.3 By Region - Global Dementia Associated with Alzimer’s Disease Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America Dementia Associated with Alzimer’s Disease Revenue, 2018-2029
        6.3.2 US Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.3.3 Canada Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.3.4 Mexico Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe Dementia Associated with Alzimer’s Disease Revenue, 2018-2029
        6.4.2 Germany Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.4.3 France Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.4.4 U.K. Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.4.5 Italy Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.4.6 Russia Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.4.7 Nordic Countries Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.4.8 Benelux Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia Dementia Associated with Alzimer’s Disease Revenue, 2018-2029
        6.5.2 China Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.5.3 Japan Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.5.4 South Korea Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.5.5 Southeast Asia Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.5.6 India Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America Dementia Associated with Alzimer’s Disease Revenue, 2018-2029
        6.6.2 Brazil Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.6.3 Argentina Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Dementia Associated with Alzimer’s Disease Revenue, 2018-2029
        6.7.2 Turkey Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.7.3 Israel Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.7.4 Saudi Arabia Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
        6.7.5 UAE Dementia Associated with Alzimer’s Disease Market Size, 2018-2029
7 Dementia Associated with Alzimer’s Disease Companies Profiles
    7.1 Merz Pharma
        7.1.1 Merz Pharma Company Summary
        7.1.2 Merz Pharma Business Overview
        7.1.3 Merz Pharma Dementia Associated with Alzimer’s Disease Major Product Offerings
        7.1.4 Merz Pharma Dementia Associated with Alzimer’s Disease Revenue in Global Market (2018-2023)
        7.1.5 Merz Pharma Key News & Latest Developments
    7.2 Novartis
        7.2.1 Novartis Company Summary
        7.2.2 Novartis Business Overview
        7.2.3 Novartis Dementia Associated with Alzimer’s Disease Major Product Offerings
        7.2.4 Novartis Dementia Associated with Alzimer’s Disease Revenue in Global Market (2018-2023)
        7.2.5 Novartis Key News & Latest Developments
    7.3 Allergan
        7.3.1 Allergan Company Summary
        7.3.2 Allergan Business Overview
        7.3.3 Allergan Dementia Associated with Alzimer’s Disease Major Product Offerings
        7.3.4 Allergan Dementia Associated with Alzimer’s Disease Revenue in Global Market (2018-2023)
        7.3.5 Allergan Key News & Latest Developments
    7.4 Pfizer
        7.4.1 Pfizer Company Summary
        7.4.2 Pfizer Business Overview
        7.4.3 Pfizer Dementia Associated with Alzimer’s Disease Major Product Offerings
        7.4.4 Pfizer Dementia Associated with Alzimer’s Disease Revenue in Global Market (2018-2023)
        7.4.5 Pfizer Key News & Latest Developments
    7.5 Daiichi Sankyo Company
        7.5.1 Daiichi Sankyo Company Company Summary
        7.5.2 Daiichi Sankyo Company Business Overview
        7.5.3 Daiichi Sankyo Company Dementia Associated with Alzimer’s Disease Major Product Offerings
        7.5.4 Daiichi Sankyo Company Dementia Associated with Alzimer’s Disease Revenue in Global Market (2018-2023)
        7.5.5 Daiichi Sankyo Company Key News & Latest Developments
    7.6 Ono Pharmaceutical
        7.6.1 Ono Pharmaceutical Company Summary
        7.6.2 Ono Pharmaceutical Business Overview
        7.6.3 Ono Pharmaceutical Dementia Associated with Alzimer’s Disease Major Product Offerings
        7.6.4 Ono Pharmaceutical Dementia Associated with Alzimer’s Disease Revenue in Global Market (2018-2023)
        7.6.5 Ono Pharmaceutical Key News & Latest Developments
    7.7 Johnson & Johnson
        7.7.1 Johnson & Johnson Company Summary
        7.7.2 Johnson & Johnson Business Overview
        7.7.3 Johnson & Johnson Dementia Associated with Alzimer’s Disease Major Product Offerings
        7.7.4 Johnson & Johnson Dementia Associated with Alzimer’s Disease Revenue in Global Market (2018-2023)
        7.7.5 Johnson & Johnson Key News & Latest Developments
    7.8 Eisai
        7.8.1 Eisai Company Summary
        7.8.2 Eisai Business Overview
        7.8.3 Eisai Dementia Associated with Alzimer’s Disease Major Product Offerings
        7.8.4 Eisai Dementia Associated with Alzimer’s Disease Revenue in Global Market (2018-2023)
        7.8.5 Eisai Key News & Latest Developments
    7.9 H. Lundbeck
        7.9.1 H. Lundbeck Company Summary
        7.9.2 H. Lundbeck Business Overview
        7.9.3 H. Lundbeck Dementia Associated with Alzimer’s Disease Major Product Offerings
        7.9.4 H. Lundbeck Dementia Associated with Alzimer’s Disease Revenue in Global Market (2018-2023)
        7.9.5 H. Lundbeck Key News & Latest Developments
    7.10 F. Hoffmann-La Roche
        7.10.1 F. Hoffmann-La Roche Company Summary
        7.10.2 F. Hoffmann-La Roche Business Overview
        7.10.3 F. Hoffmann-La Roche Dementia Associated with Alzimer’s Disease Major Product Offerings
        7.10.4 F. Hoffmann-La Roche Dementia Associated with Alzimer’s Disease Revenue in Global Market (2018-2023)
        7.10.5 F. Hoffmann-La Roche Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Dementia Associated with Alzimer’s Disease Market, Global Outlook and Forecast 2023-2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?